<DOC>
	<DOCNO>NCT00324376</DOCNO>
	<brief_summary>A randomized , cross-over , open-label study conduct evaluate equivalency , safety tolerability sevelamer per day dosing , give large meal , compare standard three time per day dosing , hemodialysis patient previously use sevelamer . Following two week Run-In period , total 24 patient randomize one follow treatment sequence : 1. sevelamer dose day large meal follow standard three time per day dose meal 2. sevelamer dose three time per day meal follow day dose large meal . Patients maintain fixed daily dose throughout treatment period base recently prescribe sevelamer dose prior screening .</brief_summary>
	<brief_title>Study Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>life expectancy least 12 month , patient receive hemodialysis three time per week 3 month longer , patient maintain sevelamer daily dose â‰¤ 9,600 mg phosphate binder serum phosphorus concentration last two measurement 3.0 6.5 mg/dL ( 0.97 2.10 mmol/L ) . active bowel obstruction , dysphagia , swallow disorder , severe gastrointestinal motility disorder , active ethanol drug abuse ( exclude tobacco ) , need antidysrhythmic antiseizure medication use control condition , poorly control diabetes mellitus hypertension , active vasculitis , active malignancy basalcell carcinoma , HIV infection , clinically significant unstable medical condition judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>